Allianz Asset Management GmbH Has $3.05 Million Stock Position in Novavax, Inc. (NASDAQ:NVAX)

Allianz Asset Management GmbH boosted its stake in shares of Novavax, Inc. (NASDAQ:NVAXFree Report) by 45.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 634,692 shares of the biopharmaceutical company’s stock after purchasing an additional 199,771 shares during the quarter. Allianz Asset Management GmbH owned 0.53% of Novavax worth $3,047,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of NVAX. BNP Paribas Financial Markets increased its holdings in shares of Novavax by 48.3% during the 4th quarter. BNP Paribas Financial Markets now owns 861,479 shares of the biopharmaceutical company’s stock worth $4,135,000 after purchasing an additional 280,381 shares during the period. Monaco Asset Management SAM increased its stake in Novavax by 123.8% during the fourth quarter. Monaco Asset Management SAM now owns 67,149 shares of the biopharmaceutical company’s stock valued at $322,000 after acquiring an additional 37,149 shares during the period. E Fund Management Co. Ltd. raised its holdings in Novavax by 69.8% in the 4th quarter. E Fund Management Co. Ltd. now owns 86,558 shares of the biopharmaceutical company’s stock valued at $415,000 after acquiring an additional 35,581 shares in the last quarter. Victory Capital Management Inc. bought a new stake in shares of Novavax in the 4th quarter worth approximately $72,000. Finally, Shah Capital Management grew its holdings in shares of Novavax by 22.9% during the 4th quarter. Shah Capital Management now owns 7,780,756 shares of the biopharmaceutical company’s stock worth $37,348,000 after purchasing an additional 1,450,000 shares in the last quarter. 53.04% of the stock is owned by institutional investors.

Insider Activity at Novavax

In other Novavax news, insider Filip Dubovsky sold 47,312 shares of the business’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $13.90, for a total value of $657,636.80. Following the transaction, the insider now owns 38,953 shares of the company’s stock, valued at $541,446.70. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.90% of the company’s stock.

Novavax Stock Performance

NVAX opened at $18.17 on Friday. The firm has a market cap of $2.55 billion, a price-to-earnings ratio of -5.73, a PEG ratio of 1.23 and a beta of 1.96. The firm’s 50-day simple moving average is $8.97 and its 200-day simple moving average is $6.28. Novavax, Inc. has a twelve month low of $3.53 and a twelve month high of $23.86.

Novavax (NASDAQ:NVAXGet Free Report) last released its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.01). The business had revenue of $93.90 million for the quarter, compared to analysts’ expectations of $71.32 million. During the same quarter in the previous year, the business posted ($3.41) EPS. The firm’s quarterly revenue was up 15.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Novavax, Inc. will post 0.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on NVAX. JPMorgan Chase & Co. upgraded Novavax from an “underweight” rating to a “neutral” rating in a research note on Friday, May 10th. TD Cowen increased their price objective on shares of Novavax from $5.00 to $10.00 and gave the company a “hold” rating in a research note on Monday, May 13th. Bank of America upgraded shares of Novavax from an “underperform” rating to a “neutral” rating and lifted their target price for the company from $4.00 to $12.00 in a research report on Friday, May 10th. HC Wainwright reissued a “buy” rating and issued a $19.00 price target on shares of Novavax in a research report on Monday, May 13th. Finally, B. Riley raised their price target on shares of Novavax from $11.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, May 23rd. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $17.50.

View Our Latest Analysis on NVAX

Novavax Company Profile

(Free Report)

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

See Also

Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.